- Home
- PNRG vs ALDX Comparison
PNRG vs ALDX Comparison
Compare PNRG & ALDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PNRG | ALDX |
|---|---|---|
| Founded | 1973 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 252.3M | 293.0M |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | PNRG | ALDX |
|---|---|---|
| Price | $183.11 | $4.86 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $9.50 |
| AVG Volume (30 Days) | 49.4K | ★ 850.7K |
| Earning Date | 11-19-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 10.31 | N/A |
| Revenue | ★ $196,237,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $36.25 |
| P/E Ratio | $18.43 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $126.40 | $1.14 |
| 52 Week High | $243.49 | $7.20 |
Technical Indicators
Market Signals| Indicator | PNRG | ALDX |
|---|---|---|
| Relative Strength Index (RSI) | 71.01 | 45.55 |
| Support Level | $166.41 | $4.67 |
| Resistance Level | $198.63 | $5.68 |
| Average True Range (ATR) | 9.80 | 0.29 |
| MACD | 3.93 | -0.03 |
| Stochastic Oscillator | 83.22 | 20.79 |
Price Performance
Historical ComparisonAbout PNRG PrimeEnergy Resources Corporation
PrimeEnergy Resources Corp is an independent oil and natural gas company that is engaged in acquiring, developing, and producing oil and natural gas. It owns producing and non-producing properties located in Texas and Oklahoma. The company's business activities include development and exploratory drilling and providing well servicing support operations for many of the onshore oil and gas wells through its subsidiaries. It is also active in the acquisition of producing oil and gas properties through joint ventures with industry partners.
About ALDX Aldeyra Therapeutics Inc.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.